Ebola River

Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine

Retrieved on: 
Wednesday, September 14, 2022
Disability, Safety, Development, Biomedical Advanced Research and Development Authority, Human, Department, Sabin, Policy, Twitter, Office of Inspector General, U.S. Department of Health and Human Services, Virus, United States Department of Health and Human Services, BARDA, Administration, Sabin Vaccine Institute, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Primate, Viral hemorrhagic fever, Human services, Vaccine, Solution, DRC, Marburg virus disease, Ecosystem, Research, GLOBE, Animal, Ebola River, Disease, Death

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.

Key Points: 
  • The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.
  • The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies.
  • In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, October 21, 2021
Safety, Death, Research, DRC, Assistant, Vaccine Research Center, Ecosystem, Filoviridae, Vaccine, Disease, Sabin, Marburg virus disease, Military personnel, Sabin Vaccine Institute, Viral hemorrhagic fever, Public Health Emergency of International Concern, Human, BARDA, Twitter, Partnership, Virus, Ebola River, Ebola, Primate, World Health Organization, Public health emergency, World, Ministry of Health (Saudi Arabia), Policy, Office of the Assistant Secretary for Preparedness and Response, Office of Inspector General, U.S. Department of Health and Human Services, Ministry, Biomedical Advanced Research and Development Authority, Polio, Infection, Public health, COVID-19, WHO, Solution, Development, GSK, GLOBE, Animal, Pharmaceutical industry

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.

Key Points: 
  • In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.
  • The two candidate vaccines, based on GSKs proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
  • Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses.
  • Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan.